dbACP: A Comprehensive Database of Anti-Cancer Peptides

415 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp00028 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 14.2% inhibition at 10-6 M
dbacp00029 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 19.7% inhibition at 10-5 M
dbacp00030 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 24.9% inhibition at 10-4 M
dbacp00031 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 30.4% inhibition at 10-3 M
dbacp00032 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 10% inhibition at 10-5 M
dbacp00033 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 8.2% inhibition at 10-4 M
dbacp00034 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 36.1% inhibition at 10-3 M
dbacp00035 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 6.5% inhibition at 10-6 M
dbacp00036 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 14% inhibition at 10-5 M
dbacp00037 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.5% inhibition at 10-4 M
dbacp00038 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 14% inhibition at 10-3 M
dbacp00039 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 9.8% inhibition at 10-6 M
dbacp00040 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 1.6% inhibition at 10-5 M
dbacp00041 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 5.4% inhibition at 10-4 M
dbacp00042 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 26.5% inhibition at 10-3 M
dbacp00043 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 12.9% inhibition at 10-6 M
dbacp00044 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 16.5% inhibition at 10-5 M
dbacp00045 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 28.1% inhibition at 10-4 M
dbacp00046 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 58.2% inhibition at 10-3 M
dbacp00047 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 3.5% inhibition at 10-6 M
dbacp00048 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 22.7% inhibition at 10-5 M
dbacp00049 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 18.9% inhibition at 10-4 M
dbacp00050 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 26.4% inhibition at 10-3 M
dbacp00051 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 2.4% inhibition at 10-5 M
dbacp00052 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.5% inhibition at 10-4 M
dbacp00053 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 6.2% inhibition at 10-6 M
dbacp00054 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 6.4% inhibition at 10-5 M
dbacp00055 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 8.2% inhibition at 10-4 M
dbacp00056 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 21.2% inhibition at 10-3 M
dbacp00057 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.5% inhibition at 10-6 M
dbacp00058 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 6.1% inhibition at 10-5 M
dbacp00059 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 3.1% inhibition at 10-4 M
dbacp00060 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 14.8% inhibition at 10-3 M
dbacp00061 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.9% inhibition at 10-5 M
dbacp00062 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.3% inhibition at 10-3 M
dbacp00063 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 4.9% inhibition at 10-6 M
dbacp00064 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 8.9% inhibition at 10-5 M
dbacp00065 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 3.4% inhibition at 10-4 M
dbacp00066 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 20.8% inhibition at 10-3 M
dbacp00067 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 10.5% inhibition at 10-6 M
dbacp00068 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 21.9% inhibition at 10-5 M
dbacp00069 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 11.8% inhibition at 10-4 M
dbacp00070 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 17.9% inhibition at 10-3 M
dbacp00071 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 3.7% inhibition at 10-6 M
dbacp00072 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 16.5% inhibition at 10-5 M
dbacp00073 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.4% inhibition at 10-4 M
dbacp00074 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 14.5% inhibition at 10-3 M
dbacp00075 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 1.1% inhibition at 10-5 M
dbacp00076 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 1.2% inhibition at 10-4 M
dbacp00077 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 17.8% inhibition at 10-3 M
dbacp00078 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 8.5% inhibition at 10-6 M
dbacp00079 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 4.9% inhibition at 10-5 M
dbacp00080 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 1.9% inhibition at 10-4 M
dbacp00081 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 16.2% inhibition at 10-3 M
dbacp00082 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.2% inhibition at 10-6 M
dbacp00083 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 17.1% inhibition at 10-5 M
dbacp00084 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.0% inhibition at 10-4 M
dbacp00085 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 20.5% inhibition at 10-3 M
dbacp00086 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.0% inhibition at 10-6 M
dbacp00087 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.7% inhibition at 10-5 M
dbacp00088 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.7% inhibition at 10-4 M
dbacp00089 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.3% inhibition at 10-3 M
dbacp00090 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 0.7% inhibition at 10-6 M
dbacp00091 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 8.3% inhibition at 10-5 M
dbacp00092 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 10.5% inhibition at 10-4 M
dbacp00093 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 21.8% inhibition at 10-3 M
dbacp00094 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 10.7% inhibition at 10-6 M
dbacp00095 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 10.0% inhibition at 10-5 M
dbacp00096 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.7% inhibition at 10-4 M
dbacp00097 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 18.7% inhibition at 10-3 M
dbacp00125 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 2.7% inhibition at 10-6 M
dbacp00126 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 2.0% inhibition at 10-5 M
dbacp00127 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 18.8% inhibition at 10-4 M
dbacp00128 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 26.7% inhibition at 10-3 M
dbacp00129 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.8% inhibition at 10-6 M
dbacp00130 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.3% inhibition at 10-5 M
dbacp00131 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.9% inhibition at 10-4 M
dbacp00132 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.2% inhibition at 10-3 M
dbacp00133 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.6% inhibition at 10-6 M
dbacp00134 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.9% inhibition at 10-5 M
dbacp00135 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 5.9% inhibition at 10-4 M
dbacp00136 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 17.9% inhibition at 10-3 M
dbacp00137 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 5.4% inhibition at 10-6 M
dbacp00138 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 7.4% inhibition at 10-5 M
dbacp00139 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 9.5% inhibition at 10-4 M
dbacp00140 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 15.7% inhibition at 10-3 M
dbacp00141 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.6% inhibition at 10-6 M
dbacp00142 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 20.4% inhibition at 10-5 M
dbacp00143 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 14.4% inhibition at 10-4 M
dbacp00144 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 23.4% inhibition at 10-3 M
dbacp00145 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 2.2% inhibition at 10-6 M
dbacp00146 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 4.2% inhibition at 10-5 M
dbacp00147 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 6.4% inhibition at 10-4 M
dbacp00148 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 6.2% inhibition at 10-3 M
dbacp00149 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 21.2% inhibition at 10-3 M
dbacp00159 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 4.6% inhibition at 10-6 M
dbacp00160 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 4.9% inhibition at 10-5 M
dbacp00161 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 12.6% inhibition at 10-4 M
dbacp00162 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 26.4% inhibition at 10-3 M
dbacp00163 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.0% inhibition at 10-6 M
dbacp00164 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.7% inhibition at 10-5 M
dbacp00165 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.6% inhibition at 10-4 M
dbacp00166 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.2% inhibition at 10-3 M
dbacp00167 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.2% inhibition at 10-5 M
dbacp00168 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.3% inhibition at 10-4 M
dbacp00169 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 19.4% inhibition at 10-3 M
dbacp00170 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 7.6% inhibition at 10-6 M
dbacp00171 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 3.8% inhibition at 10-5 M
dbacp00172 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 12.4% inhibition at 10-4 M
dbacp00173 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 22.4% inhibition at 10-3 M
dbacp00174 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 17.0% inhibition at 10-6 M
dbacp00175 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.5% inhibition at 10-5 M
dbacp00176 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.5% inhibition at 10-4 M
dbacp00177 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 25.3% inhibition at 10-3 M
dbacp00178 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.1% inhibition at 10-6 M
dbacp00179 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 6.9% inhibition at 10-5 M
dbacp00180 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.1% inhibition at 10-4 M
dbacp00181 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.6% inhibition at 10-3 M
dbacp00182 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 15.6% inhibition at 10-3 M
dbacp00192 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 1.0% inhibition at 10-6 M
dbacp00193 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 10.1% inhibition at 10-5 M
dbacp00194 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 16.8% inhibition at 10-4 M
dbacp00195 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 36.1% inhibition at 10-3 M
dbacp00196 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 4.9% inhibition at 10-6 M
dbacp00197 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 10.2% inhibition at 10-5 M
dbacp00198 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 13.3% inhibition at 10-4 M
dbacp00199 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.0% inhibition at 10-3 M
dbacp00200 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 0.8% inhibition at 10-6 M
dbacp00201 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.4% inhibition at 10-5 M
dbacp00202 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.4% inhibition at 10-4 M
dbacp00203 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 18.3% inhibition at 10-3 M
dbacp00204 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 3.3% inhibition at 10-6 M
dbacp00205 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 11.0% inhibition at 10-5M
dbacp00206 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 7.9% inhibition at 10-4 M
dbacp00207 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 23.7% inhibition at 10-3 M
dbacp00208 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 12.2% inhibition at 10-6 M
dbacp00209 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 15.5% inhibition at 10-5 M
dbacp00210 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 24.7% inhibition at 10-4 M
dbacp00211 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 29.0% inhibition at 10-3 M
dbacp00212 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 3.0% inhibition at 10-6 M
dbacp00213 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.4% inhibition at 10-5 M
dbacp00214 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 18.5% inhibition at 10-4 M
dbacp00215 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 10.6% inhibition at 10-3 M
dbacp00216 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 22.8% inhibition at 10-3 M
dbacp00226 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 13.7% inhibition at 10-6 M
dbacp00227 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 25.8% inhibition at 10-5 M
dbacp00228 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 34.7% inhibition at 10-4 M
dbacp00229 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 44.5% inhibition at 10-3 M
dbacp00230 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 8.5% inhibition at 10-6 M
dbacp00231 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.5% inhibition at 10-5 M
dbacp00232 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 15.4% inhibition at 10-4 M
dbacp00233 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 24.1% inhibition at 10-3 M
dbacp00234 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.4% inhibition at 10-6 M
dbacp00235 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.5% inhibition at 10-5 M
dbacp00236 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 11.4% inhibition at 10-4 M
dbacp00237 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 23.2% inhibition at 10-3 M
dbacp00238 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 16.2% inhibition at 10-6 M
dbacp00239 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 6.6% inhibition at 10-5 M
dbacp00240 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 5.1% inhibition at 10-4 M
dbacp00241 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 14.5% inhibition at 10-3 M
dbacp00242 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 26.4% inhibition at 10-6 M
dbacp00243 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.1% inhibition at 10-5 M
dbacp00244 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 14.6% inhibition at 10-4 M
dbacp00245 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 38.4% inhibition at 10-3 M
dbacp00246 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 17.7% inhibition at 10-6 M
dbacp00247 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 10.9% inhibition at 10-5 M
dbacp00248 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 12.1% inhibition at 10-4 M
dbacp00249 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.1% inhibition at 10-3 M
dbacp00250 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 9.6% inhibition at 10-4 M
dbacp00251 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 29.9% inhibition at 10-3 M
dbacp00279 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 3.9% inhibition at 10-5 M
dbacp00280 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 45% inhibition at 10-3 M
dbacp00281 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.3% inhibition at 10-3 M
dbacp00282 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.1% inhibition at 10-6 M
dbacp00283 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 70.7% inhibition at 10-5 M
dbacp00284 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 34.4% inhibition at 10-3 M
dbacp00285 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 9.2% inhibition at 10-3 M
dbacp00286 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 11.08% inhibition at 10-5 M
dbacp00287 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 47.0% inhibition at 10-3 M
dbacp00288 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 2.2% inhibition at 10-6 M
dbacp00289 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.1% inhibition at 10-5 M
dbacp00290 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 6.9% inhibition at 10-4 M
dbacp00291 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 25.9% inhibition at 10-3 M
dbacp00312 (HHPHG)2 HHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 11.6 µM
dbacp00313 (HHPHG)2 HHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 26.9 µM
dbacp00314 (HHPHG)3 HHPHGHHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 1.25 µM
dbacp00315 (HHPHG)3 HHPHGHHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 1.56 µM
dbacp00316 (HHPHG)4 HHPHGHHPHGHHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 0.256 µM
dbacp00317 (HHPHG)4 HHPHGHHPHGHHPHGHHPHG Synthetic Peptide Antiangiogenesis Tropomyosin binding assay Not found Tumor IC50 : 0.245 µM
dbacp00318 (RGD-4C)-GG-D(KLAKLAK)2 ACDCRGDCFCGGKLAKLAKKLAKLAK Synthetic Peptide Apoptosis inducing Internalization assay,Mitochondrial swelling assay,Cell-free apoptosis assay,Caspase activation assay KS1767 Not specified LC50 : 10 μM
dbacp01174 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 50% inhibition at 2.5 µg/ml
dbacp01175 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 40% inhibition at 5 µg/ml
dbacp01176 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 75% inhibition at 10 µg/ml
dbacp01177 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 40% inhibition at 2.5 µg/ml
dbacp01178 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 42% inhibition at 5 µg/ml
dbacp01179 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 52% inhibition at 10 µg/ml
dbacp01892 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 32.5 ± 0.5 μM
dbacp01893 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 29.5 ± 2 μM
dbacp01894 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 46.0 ± 3 μM
dbacp01895 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 50.0 ± 10 μM
dbacp01896 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 40.0 ± 3 Μm
dbacp01897 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 31.2 ± 5 μM
dbacp01898 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 22.5 ± 0 μM
dbacp01899 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 32.5 ± 4 μM
dbacp01900 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 28.0 ± 3 μM
dbacp01901 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 32.5 ± 11 μM
dbacp01902 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 40.0 ± 7 μM
dbacp01903 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 24.5 ± 0.7 μM
dbacp01904 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 34.5 ± 2 μM
dbacp01905 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 35.0 ± 7 μM
dbacp01906 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 51.0 ± 6 Μm
dbacp01907 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 40.7 ± 3 μM
dbacp01908 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 38.5 ± 4 μM
dbacp01909 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 44.0 ± 3 μM
dbacp01910 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 47.5 ± 4 μM
dbacp01911 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 44.5 ± 0.7 Μm
dbacp02160 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :10.6 ± 0.4 µM
dbacp02161 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :13.0 ± 1.0 µM
dbacp02162 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :12.1 ± 1.6 µM
dbacp02163 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :37 ± 4.3 µM
dbacp02181 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.4 ± 0.2 µM
dbacp02182 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 2.0 µM
dbacp02183 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.3 ± 0.5 µM
dbacp02184 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 1.0 µM
dbacp02206 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.8 ± 2.0 µM
dbacp02207 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 9.3 ± 1.5 µM
dbacp02208 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.1 ± 0.9 µM
dbacp02222 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 7.5 ± 0.4 µM
dbacp02627 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer IC50 : 3.2 ± 0.6 µM
dbacp02628 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay KB Oral cancer IC50 : 4.5 ± 0.5 µM
dbacp02629 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : 4.7 ± 0.4 µM
dbacp02630 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay MDA-MB-436 Breast cancer IC50 : 3.2 ± 0.4 µM
dbacp02757 Dimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))2 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 1.31 nM
dbacp02758 Dimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))2 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay DU Prostate cancer IC50 : 2.85 nM
dbacp02759 Dimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))2 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 0.62 nM
dbacp02826 EGFR-lytic YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK Synthetic Peptide Cell membrane lysis ELISA MDA-MB-231 Breast cancer IC50 : 0.12 µM
dbacp02827 EGFR-lytic YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK Synthetic Peptide Cell membrane lysis ELISA MDA-MB-231 Breast cancer IC50 : 0.46 µM
dbacp02914 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 2.5µg/ml
dbacp02915 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 5µg/ml
dbacp02916 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 10µg/ml
dbacp03289 HCAP18(109-135) FRKSKEKIGKEFKRIVQRIKDFLRNLV HCAP18 synthetic peptide Apoptosis inducing Not specified SAS-H1 Oral cancer Not found
dbacp03297 HHPHG HHPHG Synthetic Peptide Anti-angiogenesis Tropomyosin binding assay Not found Tumor IC50 : 92 µM
dbacp03530 KW5 KAAKKAAKAAKKAAKAAKKAA Synthetic peptide Through interactions with the plasma membrane MTT/MTS assay HT-29 Colon cancer IC50 : 55 ± 14 µM
dbacp04296 LTX-302 WKKW-Dip-KKWK Synthetic peptide Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 75 ± 5 µM
dbacp04297 LTX-302 WKKW-Dip-KKWK Synthetic peptide Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 73 ± 2 µM
dbacp04298 LTX-302 WKKW-Dip-KKWK Synthetic peptide Cell membrane disintegration MTT/MTS assay Kelly Brain tumor IC50 : 28 ± 0 µM
dbacp04299 LTX-315 KKWWKKW-Dip-K Synthetic peptide Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 38 ± 3 µM
dbacp04300 LTX-315 KKWWKKW-Dip-K Synthetic peptide Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 31 ± 3 µM
dbacp04301 LTX-315 KKWWKKW-Dip-K Synthetic peptide Cell membrane disintegration MTT/MTS assay Kelly Brain tumor IC50 : 14 ± 1 µM
dbacp04302 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay B16F1 Skin cancer IC50 : 13.3 µM
dbacp04303 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay A375 Skin cancer IC50 : 12.7 µM
dbacp04304 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay Fem-X Skin cancer IC50 : 15.3 µM
dbacp04305 LTX-318 OOW-Dip-OOWWO Synthetic peptide Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 248 ± 5 µM
dbacp04306 LTX-318 OOW-Dip-OOWWO Synthetic peptide Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 216 ± 36 µM
dbacp04307 LTX-318 OOW-Dip-OOWWO Synthetic peptide Cell membrane disintegration MTT/MTS assay Kelly Brain tumor IC50 : 78 ± 7 µM
dbacp04308 LTX-328 KAQ-Dip-QKQAW Synthetic peptide Necrosis MTT/MTS assay Fem-X Skin cancer IC50 : >350 µM
dbacp04643 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :3.2 ± 0.1 µM
dbacp04644 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :2.1 ± 0.1 µM
dbacp04645 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :1.8 ± 0.1 µM
dbacp04646 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :1.4 ± 0.1 µM
dbacp04794 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer > 100% cell viability at 5 µM
dbacp04795 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 60% cell viability at 50 µM
dbacp04796 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer 100% cell viability at 5 µM
dbacp04797 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer < 60% cell viability at 50 µM
dbacp04798 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 100% cell viability at 5 µM
dbacp04799 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 40% cell viability at 50 µM
dbacp04800 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer > 100% cell viability at 5 µM
dbacp04801 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 60% cell viability at 50 µM
dbacp04802 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer 100% cell viability at 5 µM
dbacp04803 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer < 60% cell viability at 50 µM
dbacp04804 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer 100% cell viability at 5 µM
dbacp04805 N29D PDEDAINDALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 40% cell viability at 50 µM
dbacp04806 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 100% cell viability at 5 µM
dbacp04807 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 40% cell viability at 50 µM
dbacp04808 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer 100% cell viability at 5 µM
dbacp04809 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer < 40% cell viability at 50 µM
dbacp04810 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 100% cell viability at 5 µM
dbacp04811 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 20% cell viability at 50 µM
dbacp04812 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 100% cell viability at 5 µM
dbacp04813 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer 40% cell viability at 50 µM
dbacp04814 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer 100% cell viability at 5 µM
dbacp04815 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay U-937 Lymphoma cancer < 40% cell viability at 50 µM
dbacp04816 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 100% cell viability at 5 µM
dbacp04817 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SNU-1 Gastric cancer < 20% cell viability at 50 µM
dbacp04818 N29N PDEDAINNALNKVCSTGRRQRSICKQLLKK Synthetic peptide Apoptotic inducing Cell viability assay SW-480 Colon cancer MIC : 5 µM
dbacp04855 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 70 µM
dbacp04856 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM
dbacp04857 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM
dbacp04858 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 40 µM
dbacp04880 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04881 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04882 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04883 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp05039 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 71.1 ± 2.84% cell viability at 20 µM
dbacp05040 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 50 ± 3.09% cell viability at 40 µM
dbacp05041 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 31.5 ± 1.49% cell viability at 60 µM
dbacp05042 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 13.8 ± 1.44% cell viability at 80 µM
dbacp05043 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 86 ± 0.57% cell viability at 10 µM
dbacp05044 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 63.8 ± 0.8% cell viability at 20 µM
dbacp05045 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 47.5 ± 1.66% cell viability at 40 µM
dbacp05046 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 26.9 ± 0.5% cell viability at 60 µM
dbacp05047 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 6.5 ± 1.07% cell viability at 80 µM
dbacp05061 P369-CTL-A2xFVB KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 8% Inhibition at 10-10 M
dbacp05062 P369-CTL-A2xFVB KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 25% Inhibition at 10-9 M
dbacp05063 P369-CTL-A2xFVB KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 80% Inhibition at 10-8 M
dbacp05064 P369-CTL-A2xFVB KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 85% Inhibition at 10-7 M
dbacp05065 P369-CTL-A2xFVB KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 92% Inhibition at 10-6 M
dbacp05066 P369-CTL-A2xneu KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 0.1% Inhibition at 10-10 M
dbacp05067 P369-CTL-A2xneu KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 1% Inhibition at 10-9 M
dbacp05068 P369-CTL-A2xneu KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 5% Inhibition at 10-8 M
dbacp05069 P369-CTL-A2xneu KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 10% Inhibition at 10-7 M
dbacp05070 P369-CTL-A2xneu KIFGSLAFL Synthetic Peptide Antiangiogenis; Immune regulation Peptide dose curve assay N202.A2 Tumor 20% Inhibition at 10-6 M
dbacp05098 p776 GVGSPYVSRLLGICL Synthetic Peptide Inducing apoptosis ELISPOT assay Not found Tumor Not found
dbacp05102 p85 LIAHNQVRQV Synthetic Peptide Inducing apoptosis ELISPOT assay Not found Tumor Not found
dbacp05307 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 10.6 % inhibition of cell proliferation at 1 nM
dbacp05308 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 18.2 % inhibition of cell proliferation at 10 nM
dbacp05309 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 30.7 % inhibition of cell proliferation at 100 nM
dbacp05310 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 43.1 % inhibition of cell proliferation at 1 µM
dbacp05311 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 98.3 % inhibition of cell proliferation at 10 µM
dbacp05312 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 24.2 % inhibition of cell proliferation at 1 nM
dbacp05313 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 37.8 % inhibition of cell proliferation at 10 nM
dbacp05314 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 48.2 % inhibition of cell proliferation at 100 nM
dbacp05315 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 59.6 % inhibition of cell proliferation at 1 µM
dbacp05316 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 84.5 % inhibition of cell proliferation at 10 µM
dbacp05317 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 16.5 % inhibition of cell proliferation at 1 nM
dbacp05318 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 14.2 % inhibition of cell proliferation at 10 nM
dbacp05319 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 16.8 % inhibition of cell proliferation at 100 nM
dbacp05320 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 21.7 % inhibition of cell proliferation at 1 µM
dbacp05321 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 27.9 % inhibition of cell proliferation at 10 µM
dbacp05322 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 10.4 % inhibition of cell proliferation at 1 nM
dbacp05323 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 18.7 % inhibition of cell proliferation at 10 nM
dbacp05324 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 34.7 % inhibition of cell proliferation at 100 nM
dbacp05325 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 54.3 % inhibition of cell proliferation at 1 µM
dbacp05326 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 94.5 % inhibition of cell proliferation at 10 µM
dbacp05327 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer ED50 : 2.1 µM
dbacp05328 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer ED50 : 0.210 µM
dbacp05329 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer ED50 : >10 µM
dbacp05330 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer ED50 : 0.29 µM
dbacp05438 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay HL-60 Leukemia cancer At 100 µM 90% viablity
dbacp05439 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay MDA-MB-231 Breast cancer At 100 µM 55% viablity
dbacp05440 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay HeLa Cervical cancer At 100 µM 50% viablity
dbacp05441 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay B16F10-Nex 2 Skin cancer At 100 µM 50% viablity
dbacp05442 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay A-2058 Skin cancer At100 µM 30% viablity
dbacp05443 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay Skmel-25 Skin cancer At 100 µM 55 - 60% viablity
dbacp05444 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay Skmel-28 Skin cancer At 100 µM 35 - 40% viablity
dbacp05706 PTP-7a FLGALFHALSKLL Synthetic peptide Inducing cell membrane damage MTT/MTS assay A-549 Lung cancer IC50 : 28 µM
dbacp05707 PTP-7b FLGALFKALSHLL Synthetic peptide Inducing cell membrane damage MTT/MTS assay A-549 Lung cancer IC50 : 32 µM
dbacp05825 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 0% apoptosis at 10 µM
dbacp05826 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 10% apoptosis at 20 µM
dbacp05827 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 30% apoptosis at 50 µM
dbacp05828 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 30% apoptosis at 10 µM
dbacp05829 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 80% apoptosis at 20 µM
dbacp05830 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 80% apoptosis at 50 µM
dbacp05831 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 20% apoptosis at 10 µM
dbacp05832 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor > 50% apoptosis at 20 µM
dbacp05833 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 30% apoptosis at 50 µM
dbacp05834 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 15% apoptosis at 10 µM
dbacp05835 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 20% apoptosis at 20 µM
dbacp05836 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 50% apoptosis at 50 µM
dbacp05839 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 8% apoptosis at 10 µM
dbacp05840 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 45% apoptosis at 20 µM
dbacp05841 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 65% apoptosis at 50 µM
dbacp05842 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 25% apoptosis at 10 µM
dbacp05843 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 66% apoptosis at 20 µM
dbacp05844 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 68% apoptosis at 50 µM
dbacp05845 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 43% apoptosis at 10 µM
dbacp05846 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 46% apoptosis at 20 µM
dbacp05847 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 79% apoptosis at 50 µM
dbacp05848 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 23% apoptosis at 10 µM
dbacp05849 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 35% apoptosis at 20 µM
dbacp05850 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 55% apoptosis at 50 µM
dbacp05851 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 1% apoptosis at 10 µM
dbacp05852 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 2% apoptosis at 20 µM
dbacp05853 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 3% apoptosis at 50 µM
dbacp05854 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 2% apoptosis at 10 µM
dbacp05855 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 1% apoptosis at 20 µM
dbacp05856 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 5% apoptosis at 50 µM
dbacp05857 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 1% apoptosis at 10 µM
dbacp05858 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 2% apoptosis at 20 µM
dbacp05859 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 3% apoptosis at 50 µM
dbacp05860 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 0% apoptosis at 10 µM
dbacp05861 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 1% apoptosis at 20 µM
dbacp05862 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 2% apoptosis at 50 µM
dbacp06023 Sansalv amide A NA Synthetic Peptide Apoptosis Cell viability assay S2-13 Pancreatic cancer EC50 : 7.5 µM
dbacp06169 SVS-1 KVKVKVKVpPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer Not found
dbacp06171 SVS-1 KVKVKVKVpPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : 8.1 ± 0.8 µM
dbacp06172 SVS-1 KVKVKVKVpPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MDA-MB-436 Breast cancer IC50 : 5.6 ± 0.5 µM
dbacp06173 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer IC50 : >100 µM
dbacp06174 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay KB Oral cancer IC50 : >100 µM
dbacp06175 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : >100 µM
dbacp06176 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MDA-MB-436 Breast cancer IC50 : >100 µM
dbacp06177 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Calu-6 Lung cancer 35% survival rate at 10 µM
dbacp06178 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Calu-6 Lung cancer 0% survival rate at 100 µM
dbacp06179 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Jurkat Blood cancer ~60% survival rate at 10 µM
dbacp06180 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Jurkat Blood cancer 0% survival rate at 100 µM
dbacp06181 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay SNU-601 Gastric cancer ~20% survival rate at 10 µM
dbacp06182 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay SNU-601 Gastric cancer 0% survival rate at 100 µM
dbacp06293 Tetramer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))4 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 0.96 nM
dbacp06294 Tetramer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))4 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay DU Prostate cancer IC50 : 1.30 nM
dbacp06295 Tetramer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))4 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 0.64 nM
dbacp06346 Trimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))3 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 1.70 nM
dbacp06347 Trimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))3 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay DU Prostate cancer IC50 : 3.88 nM
dbacp06348 Trimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))3 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 3.00 nM
dbacp06404 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 49.4% Cytotoxic at 0.1 µg/ml
dbacp06405 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 51.2% Cytotoxic at 1 µg/ml
dbacp06406 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 53.0% Cytotoxic at 10 µg/ml
dbacp06407 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 61.2% Cytotoxic at 100 µg/ml
dbacp06408 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 39.0% Cytotoxic at 0.1 µg/ml
dbacp06409 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 20.8% Cytotoxic at 1 µg/ml
dbacp06410 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 33.8% Cytotoxic at 10 µg/ml
dbacp06411 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 35.6% Cytotoxic at 100 µg/ml
dbacp08045 R11-NLS-pep8 RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa NKp44 derived synthetic peptide NKp44-pep8 inhibits PCNA function PrestoBlue assay B-16 Skin Cancer ED50 = 7.1 μM
dbacp08046 R11-NLS-pep8 RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa NKp44 derived synthetic peptide NKp44-pep8 inhibits PCNA function PrestoBlue assay PANC-1 Pancreatic Cancer ED50 = 7.8 μM
dbacp08047 R11-NLS-pep8 RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa NKp44 derived synthetic peptide NKp44-pep8 inhibits PCNA function PrestoBlue assay HepG-2 Liver Cancer ED50 = 5.9 μM
dbacp08048 R11-NLS-pep8 RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa NKp44 derived synthetic peptide NKp44-pep8 inhibits PCNA function PrestoBlue assay MDA-MD-231 Breast Cancer ED50 = 5.6 μM